The OrigAMI-3 Study
A study for people with colorectal cancer that has spread to other parts of the body (metastasized)
This study is testing how safe and effective a study medication is for people with colorectal cancer that has spread to other parts of the body (metastasized).
You may be considered for the OrigAMI-3 Study based on your disease status.
Everyone who participates in the study will receive an approved chemotherapy typically given for colorectal cancer. In addition to chemotherapy, you will receive:
The study medication OR a targeted medication approved for colorectal cancer.
The goal of this study is to test how well the study medication works to stop or slow your cancer compared to the approved medications for colorectal cancer.
Colorectal cancer starts in the colon or the rectum. These cancers can also be called colon cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common.
Participants will be randomly assigned (like the flip of a coin) to one of the two groups. The study schedule is broken out into groups that repeat every 28 days. This is called a 28-day cycle
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind:
Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.